Impact of ETI Therapy on Chronic Inhaled Medication Refill Rates in Cystic Fibrosis
发布者：Unknown
·发布于: 2025-12-13
A discussion exploring how the introduction of elexacaftor/tezacaftor/ivacaftor (ETI) therapy influences prescription refill rates for chronic inhaled medications among individuals diagnosed with cystic fibrosis.